2 options
Making Objective Drug Evidence Revisions for New Labeling Act of 2020 : report (to accompany H.R. 5668) (including cost estimate of the Congressional Budget Office).
- Format:
- Book
- Government document
- Author/Creator:
- United States. Congress. House. Committee on Energy and Commerce, author.
- Series:
- United States. Congress. House. Report ; 116-573.
- Report / 116th Congress, 2d session, House of Representatives ; 116-573
- Language:
- English
- Subjects (All):
- Generic drugs--Law and legislation--United States.
- Generic drugs.
- Generic drugs--Labeling--United States.
- Generic drugs--Safety regulations--United States.
- Warning labels--Government policy--United States.
- Warning labels.
- Drugs--Safety regulations.
- United States.
- Genre:
- legislative records.
- Legislative materials.
- Physical Description:
- 1 online resource (14 pages).
- Place of Publication:
- [Washington, D.C.] : [U.S. Government Publishing Office], [2020]
- Notes:
- "November 16, 2020."
- Includes bibliographical references.
- Description based on online resource; PDF version; title from caption (govinfo, viewed Nov. 30, 2020).
- Other Format:
- Microfiche version: United States. Congress. House. Committee on Energy and Commerce. Making Objective Drug Evidence Revisions for New Labeling Act of 2020
- Print version: United States. Congress. House. Committee on Energy and Commerce. Making Objective Drug Evidence Revisions for New Labeling Act of 2020
- OCLC:
- 1224541640
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.